Skip to main content

MiMedx Group (MDXG) Gets a Buy from Northland Securities

Tipranks - Tipranks - Tue Nov 4, 2025

In a report released today, Carl Byrnes from Northland Securities maintained a Buy rating on MiMedx Group, with a price target of $12.00. The company’s shares opened today at $7.48.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

According to TipRanks, Byrnes is an analyst with an average return of -4.1% and a 36.78% success rate. Byrnes covers the Healthcare sector, focusing on stocks such as Brainsway, BioLife Solutions, and Alvotech.

In addition to Northland Securities, MiMedx Group also received a Buy from Craig-Hallum’s Chase Knickerbocker in a report issued today. However, on October 30, TR | OpenAI – 4o reiterated a Hold rating on MiMedx Group (NASDAQ: MDXG).

See today’s best-performing stocks on TipRanks >>

Based on MiMedx Group’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $98.61 million and a net profit of $9.62 million. In comparison, last year the company earned a revenue of $87.21 million and had a net profit of $17.63 million

Read More on MDXG:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).